Results 111 to 120 of about 32,684 (149)

Risk of Guillain-Barré Syndrome after Laboratory-Confirmed Dengue Infection. [PDF]

N Engl J Med
Cerqueira-Silva T, Paixão E, França GVA, Tenório LXS, Amaral MC, Santos NM, Pearce N, Boaventura VS, Barral-Netto M.   +8 more
europepmc   +1 more source

Guillain-Barré Syndrome: Progress in Diagnosis, Biomarkers, Neuroimaging and Management. [PDF]

Immunotargets Ther
Freiha J, Min YG, Osman C, Rajabally YA.
europepmc   +1 more source

U1 Small Nuclear Ribonucleoprotein Autoantibodies Reflect the Disruption of the Blood-Nerve Barrier in Guillain-Barré Syndrome. [PDF]

Int J Mol Sci
Shimizu F, Koga M, Yamanaka N, Nakamori M.   +3 more
europepmc   +1 more source

Efgartigimod for Guillain-Barré syndrome: a retrospective analysis of efficacy and safety. [PDF]

Ther Adv Neurol Disord
Bi Z, Ye X, Liu P, Lu M, Liu H, Chen M.
europepmc   +1 more source

Rapid neurological recovery in Guillain-Barré syndrome treated with efgartigimod. [PDF]

Sci Rep
Cheng Y, Li W, Xie S, Guo S, Li C, Zhang M, Wang Y.   +6 more
europepmc   +1 more source

Guillain-Barré syndrome. [PDF]

BJA Educ
Hunter J, English WA, Wiegers EJA, Jacobs BC.   +3 more
europepmc   +1 more source

Lessons from a Severe Case of Fulminant Guillain-Barré Syndrome: A Case Report. [PDF]

Reports (MDPI)
Saunders JA, Patel SS, Varkey TC, Shaikh S, Conforti A, Murthy G.   +5 more
europepmc   +1 more source

Recurrence of Guillain-Barré Syndrome Is not Uncommon, and a Relapse May Require More Aggressive Treatment than the Original Condition. [PDF]

Clin Pract Cases Emerg Med
Finsterer J.
europepmc   +1 more source

Patient Outcomes Among Medicare Beneficiaries With Guillain-Barré Syndrome. [PDF]

J Peripher Nerv Syst
Wright B, Eiffert SR, Cirincione A, Nardin J, Howard JF, Traub RE.   +5 more
europepmc   +1 more source

Severe Guillain-Barré syndrome after mRNA COVID-19 vaccination with rapid deterioration and recovery: a case report. [PDF]

Oxf Med Case Reports
Samli R, Al-Diri B, Jamileh E, Hudaib T.
europepmc   +1 more source